Efonidipine
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C34H38N3O7P |
Molar mass | 631.65 g/mol |
3D model (JSmol) | |
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel.
It has also been studied in atherosclerosis[1] and acute renal failure.[2]
References
- ↑ Toyoda K, Kitahara M, Yamashita T; et al. (1994). "[Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits]". Nippon Yakurigaku Zasshi (in Japanese). 103 (5): 231–9. PMID 8188119. Unknown parameter
|month=
ignored (help) - ↑ Shudo C, Masuda Y, Sugita H, Tanaka S, Tomita K (1994). "Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats". Gen. Pharmacol. 25 (7): 1451–8. PMID 7896060. Unknown parameter
|month=
ignored (help)
- Template:Ja icon Landel ランデル (PDF) Shionogi & Co. April 2005.
Categories:
- Pages with script errors
- Pages with citations using unsupported parameters
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- CS1 maint: Unrecognized language
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Calcium channel blockers